Dicumarol
(Dicumarols)PreclinicalSmall molecule
AbbVieDicumarol is one of 14 small molecule programs targeting Head Injury. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
13
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Head Injury
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Epsom Salt
FFresenius Kabi Oncology Ltd.
Approved
Cyklokapron
AAmring
Phase 3
Crestor
AstraZenecaPhase 2
Human Serum Albumin
FFresenius
Phase 3
Osmitrol
BB. Braun Medical Inc.
Phase 2
Depakote
TevaPreclinical
Oxycyte
TTenax Therapeutics, Inc.
Phase 2
Direct Anticoagulant
BayerPreclinical
Cortrosyn
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
DICUMAROL
NDA NDA005509
Jan 1, 1982
DICUMAROL
NDA NDA005545
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dicumarols. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]